APA (7th ed.) Citation

J, Z., S, A., X, Z., X, W., G, C., & Y, W. (2026). Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy. Frontiers in immunology, 17, 1787013. https://doi.org/10.3389/fimmu.2026.1787013

Chicago Style (17th ed.) Citation

J, Zhou, Ai S, Zhang X, Wang X, Chen G, and Wang Y. "Efficacy and Safety of Modified-dose Obinutuzumab in the Treatment of Refractory Membranous Nephropathy." Frontiers in Immunology 17 (2026): 1787013. https://doi.org/10.3389/fimmu.2026.1787013.

MLA (9th ed.) Citation

J, Zhou, et al. "Efficacy and Safety of Modified-dose Obinutuzumab in the Treatment of Refractory Membranous Nephropathy." Frontiers in Immunology, vol. 17, 2026, p. 1787013, https://doi.org/10.3389/fimmu.2026.1787013.